Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28401130 | 1.00 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL25751671 | 0.90 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL28403806 | 0.87 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL28403807 | 0.87 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL20603082 | 0.85 | FOLH1 (0.33) | HPGDCYP2C9PPARGPPARA | |
| SCHEMBL20603083 | 0.85 | FOLH1 (0.33) | HPGDCYP2C9PPARGPPARA | |
| SCHEMBL20603097 | 0.84 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL20603096 | 0.84 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL18613472 | 0.81 | MAPT (0.33) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL28527043 | 0.79 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109675-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260103696-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-16 | — | — | US | disclosed |
| US-12496310-B2 | Compositions and methods for adoptive cell therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-16 | — | — | US | disclosed |
| EP-3645561-B1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12241097-B2 | Compositions and methods for adoptive cell therapy for cancer | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-03-04 | — | — | US | disclosed |
| US-12178830-B2 | Compositions and methods for adoptive cell therapy for cancer | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-06-22 | — | — | US | disclosed |
| CN-111315872-A | Compositions and methods for adoptive cell therapy of cancer | 纪念斯隆-凯特林癌症中心 | 2020-06-19 | — | — | CN | disclosed |
| CN-111212849-A | Compositions and methods for adoptive cell therapy of cancer | 纪念斯隆-凯特林癌症中心 | 2020-05-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103696-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | CCRL2, CCR3, LY6K | ALDH1A1 2196/4885MEN1 4273/4885KMT2A 1509/4885 |
| US-12496310-B2 | Compositions and methods for adoptive cell therapy | HAVCR2, CD4, CCR1 | ALDH1A1 890/4885MEN1 4145/4885KMT2A 1925/4885 |
| US-12241097-B2 | Compositions and methods for adoptive cell therapy for cancer | CD2, PBK, CD4 | ALDH1A1 808/4885MEN1 3185/4885KMT2A 1434/4885 |
| US-20260109675-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | IL2RA, CCR3, CD4 | ALDH1A1 1620/4885MEN1 2579/4885KMT2A 1827/4885 |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | HAVCR2, CD4, CCR1 | ALDH1A1 890/4885MEN1 4145/4885KMT2A 1925/4885 |
| US-12178830-B2 | Compositions and methods for adoptive cell therapy for cancer | CD2, PBK, CD4 | ALDH1A1 808/4885MEN1 3185/4885KMT2A 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.